Protein minimization highlights essential determinants of structure and function. Minimal models of proinsulin and insulin-like growth factor I contain homologous A and B domains as single-chain analogues. Such models (designated mini-proinsulin and mini-IGF-I) have attracted wide interest due to their native foldability but complete absence of biological activity. The crystal structure of mini-proinsulin, determined as a T 3 R 3 hexamer, is similar to that of the native insulin hexamer. Here, we describe the solution structure of a monomeric mini-proinsulin under physiologic conditions and compare this structure to that of the corresponding two-chain analogue. The two proteins each contain substitutions in the B-chain (His B10 3 Asp and Pro B28 3 Asp) designed to destabilize self-association by electrostatic repulsion; the proteins differ by the presence or absence of a peptide bond between Lys B29 and Gly A1 . The structures are essentially identical, resembling in each case the Tstate crystallographic protomer. Differences are observed near the site of cross-linking: the adjoining A1-A8 a-helix (variable among crystal structures) is less well-ordered in mini-proinsulin than in the two-chain variant. The single-chain analogue is not completely inactive: its af®nity for the insulin receptor is 1500-fold lower than that of the two-chain analogue. Moreover, at saturating concentrations mini-proinsulin retains the ability to stimulate lipogenesis in adipocytes (native biological potency). These results suggest that a change in the conformation of insulin, as tethered by the B29 ± A1 peptide bond, optimizes af®nity but is not integral to the mechanism of transmembrane signaling. Surprisingly, the tertiary structure of mini-proinsulin differs from that of mini-IGF-I (mainchain rms deviation 4.5 A Ê ) despite strict conservation of non-polar residues in their respective hydrophobic cores (side-chain rms deviation 4.9 A Ê ). Three-dimensional pro®le scores suggest that the two structures each provide acceptable templates for threading of insulin-like sequences. Mini-proinsulin and mini-IGF-I thus provide examples of homologous protein sequences encoding non-homologous structures.
Introduction
Insulin provides a model for studies of protein folding and recognition (Baker et al., 1988) . The mature hormone contains A and B chains (of 21 and 30 residues) and is stabilized by three disul®de bridges (A6 ± A11, A7 ±B7 and A20 ±B19). The structure of insulin, investigated in multiple crystal forms, is remarkable for conformational variability (Bentley et al., 1978; Chothia et al., 1983; Derewenda et al., 1989; Badger, 1992; Smith & Dodson, 1992; Smith & Ciszak, 1994; Whittingham et al., 1994) . Binding of insulin to the insulin receptor activates the receptor tyrosine kinase and in turn a complex post-receptor signaling pathway (Steiner et al., 1990) . Despite the central role of this pathway in the hormonal control of metabolism, how insulin binds to and triggers its receptor is poorly understood. These mechanisms have been investigated by extensive structure-based analogue design (Brange et al., 1988; Markussen et al., 1987 Markussen et al., , 1988 Weiss et al., 1989; DiMarchi et al., 1992; Ciszak et al., 1995) . Although an overall receptorbinding surface has been proposed (Pullen et al., 1976; Liang et al., 1992; Baker et al., 1988; Dai et al., 1988) , relative activities of analogues are not consistently predicted by crystal structures (Kobayashi et al., 1982 (Kobayashi et al., , 1986 Nakagawa & Tager, 1987; Mirmira & Tager, 1989; Hua et al., , 1993a . Of broad in¯uence has been the ®nding that the crystal structure of an inactive single-chain analogue (``mini-proinsulin''; Markussen, 1985a,b) is essentially identical to that of native insulin (Figure 1A and B; Derewenda et al., 1991) . The inter-chain peptide bond in mini-proinsulin (asterisk in Figure 1B ) is proposed to constrain the protein from adopting a novel conformation on receptor binding. The relationship between conformational change in the hormone and the mechanism of transmembrane signaling is not understood.
Whereas insulin binds to its receptor as a Zn 2 -free monomer, the structure of mini-proinsulin was Figure 1 . A, T 3 R 3 crystal structure of mini-proinsulin (Derewenda et al., 1991) . T-state protomers are shown in green; R-state protomers in red. B, Superposition of main-chains of mini-proinsulin T-state protomer (green) and native insulin protomer (white). An asterisk indicates the position of the peptide cross-link in mini-proinsulin connecting B29 and A1. C, Superposition (stereo pair) of the T-state protomer of the mini-proinsulin (green) and mini-IGF-I (red; Gill et al., 1996; DeWolf et al., 1996) according to the main-chain atoms of residues B9 to B19. determined as a T 3 R 3 Zn 2 -stabilized hexamer ( Figure 1A) . What is the structure of mini-proinsulin as a monomer in solution? This question has been raised with particular clarity by recent studies of the homologous insulin-related growth factor I (IGF-I). A corresponding``mini-IGF-I'' has been constructed and like mini-proinsulin is completely inactive . The structure of mini-IGF-I has been determined as a monomer in solution by two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy (DeWolf et al., 1996) . Unexpectedly, a global change was observed in the orientation of its A and B domains ( Figure 1C ). This change, which results in dramatic reorganization of the hydrophobic core ( Figure 2 ) and putative receptor-binding surface, rationalizes the protein's loss of biological activity. Would a miniproinsulin monomer in solution exhibit analogous structural reorganization, and if so, would such reorganization confound or alter the present interpretation of its inactivity? To address these questions we prepared a monomeric analogue of mini-proinsulin. Design of the monomer is based on the selective destabilization of self-association by electrostatic repulsion (Brange et al., 1988) . Here we describe the solution structure and function of this monomer and its comparison with the corresponding two-chain analogue. The structural studies support the original ®ndings of Derewenda et al. (1991) in the crystal state and in addition demonstrate a propagated effect of the B29 ±A1 peptide bond on the adjoining A-chain a-helix. Figure 2 . A, T-state protomer of mini-proinsulin in the crystallographic hexamer (Derewenda et al., 1991 et al., 1996) in a similar orientation. The asterisk indicates the peptide bond between the A and B domains. Homologous side-chains are shown in corresponding colors as for A. C, Stereo pair showing relative displacement of the conserved side-chains in the hydrophobic cores of mini-proinsulin and mini-IGF-I. The numbering scheme at the left refers to the mini-IGF-I sequence. Leu14 in IGF-I corresponds to Leu B15 in mini-proinsulin; Phe23 in mini-IGF-I corresponds to PheB24 in mini-proinsulin, etc. The orientation is the same as in A and B.
Structure and Function of Mini-proinsulin
Corresponding biological assays distinguish between effects of the cross-link on af®nity and potency. Together, our results suggest that a change in the conformation of insulin, as tethered by the B29 ±A1 peptide bond, optimizes af®nity but is not integral to the mechanism of transmembrane signaling. The structures of mini-proinsulin and mini-IGF-I provide, in their native states, natural examples of protein alchemy, homologous protein sequences encoding non-homologous structures.
Results
The primary structure of proinsulin contains A, B and C domains (Steiner et al., 1985) . Information required for speci®cation of disul®de pairing, protein folding and receptor binding is contained in the A and B domains (Katsoyannis, 1966; Chance et al., 1981; Wang & T'sou, 1991) . The C domain, not well conserved in sequence or length among vertebrate insulins, provides a topological tether. Deletion of the C domain and the C-terminal residue of the B-chain (Thr
B30
) yields a single-chain analogue (``mini-proinsulin'') with native foldability (Markussen, 1985a) , self-association and hexameric structure ( Figure 1A ; Derewenda et al., 1991) but without biological activity (Markussen, 1985b) . Previous 1 H-NMR studies of mini-proinsulin have been limited by aggregation even in organic cosolvents at extreme pH (20% deuteroacetic acid; Weiss et al., 1989) .
To enable NMR studies of mini-proinsulin in physiologic solution, a monomeric analogue was prepared by total synthesis (see Methods). Substitutions in the B-chain (B10 Asp and B28 Asp ) were introduced to destabilize dimer and hexamer-forming surfaces (Brange et al., 1988; Weiss et al., 1991; Brems et al., 1992; Shoelson et al., 1992) . The corresponding two-chain analogue (des (Thr  B30 )[B10  Asp ,  B28 Asp ]-human insulin) was prepared by standard chain combination as an untethered control. Oxidative folding (single-chain analogue) and chain combination (two-chain analogue) in each case yielded a single species (disul®de isomer) with an ef®ciency similar to that observed in the total synthesis of native insulin. Native pairing (cystine residues A6-A11, A7-B7 and A20-B19) was veri®ed by NMR analysis of inter-residue NOEs; non-native disul®de isomers (Sieber et al., 1978; Hua et al., 1995) were not observed. Although a variety of B29 ± A1 chemical cross-links have been described (Nakagawa & Tager, 1989) , the covalent structure of the B29-A1 peptide bond employed in the present study is identical to that characterized by X-ray crystallography (Derewenda et al., 1991) .
Activities of the single and two-chain analogues relative to native porcine insulin were measured by two independent assays ( Figure 3 and Table 1 ). Speci®c binding to the insulin receptor was measured in a rat liver membrane fraction; relative activity in this assay is de®ned as the ratio of porcine insulin to analogue required to displace 50% of speci®cally bound [
125 I]insulin. Signaling through the insulin receptor was measured by the ability of the analogue to stimulate lipogenesis in isolated rat adipocytes; relative activity in this assay is de®ned as the ratio of porcine insulin to analogue required to achieve 50% of maximal conversion of [3- 3 H]glucose into organic-extractable material (glycogen). The two-chain analogue exhibits relative activities of 300% and 150% in these respective assays. The activity of the single-chain analogue was in each case decreased by 1500-fold relative to the two-chain variant. Such a large decrement in binding is uncommon among mutant insulins and, as previously emphasized (Derewenda et al., 1991) , demonstrates the importance of conformational¯exibility in receptor binding. As saturating concentrations of analogue are approached, however, stimulation of lipogenesis by mini-proinsulin progressively approaches that achieved by native insulin at corresponding levels of receptor occupancy ( Figure 3A ). Such retention of potency demonstrates that transmembrane signaling by the insulin receptor (Steiner et al., 1990) is not coupled to those changes in the conformation of insulin that are constrained by the interchain cross-link. The relative af®nities of the single and two-chain analogues for the insulin receptor are in each case twofold higher than their relative biological potencies in lipogenesis (Table 1) .
H-NMR spectroscopy
1 H-NMR spectra of single and two-chain analogues at pH 6.8 and 25
C are shown in Figure 4 . Two-dimensional spectra in each case contain the 50 expected unique spin systems. Extensive resonance broadening due to self-association, characteristic of native insulin under these conditions (Roy et al., 1990; Weiss et al., 1991) , is in neither case observed. Overall dispersion of chemical shifts in the two spectra is similar. Aromatic resonances of Phe and Tyr in each case exhibit 2-fold symmetry at 4 to 40 C as in native insulin (Weiss et al., 1989) . The pattern of chemical shifts is similar to that of engineered insulin monomers Ludvigsen et al., 1994; Olsen et al., 1996; Hua et al., 1996b) and distinct from that of an engineered dimer (Jùrgensen et al., 1992) . The pattern of protection of amide protons (as evaluated on the 500 ms time-scale by analysis of exchange crosspeaks in H 2 O; Hua et al., 1996b) corresponds in each case to inferred hydrogen bonds in the Bchain a-helix and C-terminal A-chain helix; absence of protection in the N-terminal region of the Achain is consistent with the structural variability of this region among crystal forms (Baker et al., 1988; Badger, 1992 Hua et al., 1993b) . Sequential assignment ( Figure 5 ) demonstrates that the single and two-chain analogues retain the secondary structure of the T-state. However, the N-terminal a-helix of the A-chain (residues A2 to A8) is less well de®ned in mini-insulin than in the two-chain variant. Although due in part to``absence of evidence'' (due to fortuitous overlap of resonances and differential broadening of resonances in the spectrum of mini-proinsulin), there is in part``evidence of absence'': some helix-related NOEs observed in the two-chain variant and predicted to occur in wellresolved regions of the mini-proinsulin spectrum are not observed. These are d ab(i,i 3) contacts between residues A2 to A5, A3 to A6 and A4 to A7 ( Figure 5 ). A d aN(i,i 4) contact is retained in the single-chain analogue between residues A3 and A7. Despite such differences in segmental NOEs adjoining the cross-link, an overall correspondence in chemical shifts is observed: in particular, residues with large or small secondary shifts (de®ned as the difference between observed chemical shifts and those expected in a random coil; Wuthrich, 1986) in the single-chain analogue exhibit a corresponding pattern of secondary shifts in the twochain control. These overall similarities demonstrate that, despite local differences in the adjoining A-chain a-helix, imposition of the covalent B29 ±A1 cross-link does not introduce an overall change in the structure of the protein. This is explicitly demonstrated by comparison of inter-residue NOEs, including those involving conserved sidechains Ile A2 and Val A3 ( Figure 6 ). Difference in chemical shifts are shown by residue and proton class in Figure 7 . As expected, the largest changes (asterisks) are observed toward the C terminus of the B-chain and N terminus of the Achain (i.e., the site of the B29 ± A1 peptide cross- NOEs are also observed in each helix in the two-chain variant (A2 ± A6, A12± A16, B10 ± B14, B17± B20 and B14± B18) and in the single-chain analogue (A3 ± A7, A13 ± A17, B14± B18 and B15± B19). These support their classi®cation as a-helices (as distinct from 3 10 helices) and hence in the imposition of a-helix-speci®c hydrogen bonds at sites of protected amide proton exchange. ; the asterisk in B indicates A2 ± B29 contact across the peptide cross-link. Other assignments: a, A2 ± B28, b, A2 ± B26, c, A16 ± B16' d, A3± B26. link). Small changes are observed to be distributed throughout the protein. No overall pattern is discerned in the sign or magnitude of these changes. These observations suggest that the presence of the peptide cross-link is associated with an adjustment in the details of the structure. Such non-local adjustments occur in the crystal structure of the mini-proinsulin hexamer despite its overall similarity to the native hexamer (Derewenda et al., 1991) . The cross-link also affects resonance line widths. As expected, motional narrowing ordinarily observed at the chain termini (B27 to B30 and A1) is not seen in the spectrum of the single-chain analogue. In addition, the variable anomalous broadening characteristic of the 1 H-NMR spectrum of insulin (Weiss et al., 1989; Kline & Justice, 1990 ) is accentuated in mini-proinsulin. This is most evident in the DQF-COSY spectrum due to enhanced sensitivity of cross-peak intensities to antiphase cancellation (Weiss et al., 1984) . Examples among aromatic resonances are shown in Figure 8 (asterisks in Figure 8B ). Differential broadening of Tyr B16 and Phe B24 without change in chemical shifts is ascribed to intermediate exchange among conformational substates; presumably, cleavage of the peptide bond leads to more complete averaging of chemical shifts on the NMR time scale. These and other affected resonances are both near to (A1 ±A4) and distant from the site of cross-link (B16 and B24; Figure 8D ), suggesting a coupling between overall low-frequency modes (Weiss et al., 1989; Kline & Justice, 1990) and¯uctuations at the chain termini. Similar observations were described in NMR studies of a des(B26-B30)-pentapeptide insulin fragment (DPI; . Non-local effects of B29 ± A1 cross-links on the dynamics of insulin have simulated by molecular dynamics (Kruger et al., 1994) and investigated using a variety of chemical tethers (Nakagawa & Tager, 1989; Brems et al., 1991) .
Solution structures
Solution structures of the single and two-chain analogues have been calculated by distance geometry and simulated annealing. Restraint information and statistics are summarized in Table 2 . (The number of restraints obtained in studies of the two-chain analogue is larger than that obtained in studies of mini-proinsulin due to differential resonance broadening in the latter leading to apparent attenuation of selected NOEs.) The solution structure of the two-chain analogue ( Figure 9A ) is similar to a set of crystallographic T-states and consistent with previous studies of monomeric analogues (Olsen et al., 1996; Hua et al., 1996b) . rms deviations{ among all main-chain atoms (including poorly ordered chain termini) relative to an average structure (0.68 A Ê ) are similar to rms deviations among inequivalent crystallographic Tstates (0.41 A Ê ); in particular, the ensemble is equally consistent with the main-chain structure of either protomer 1 or 2 of the T 6 Zn hexamer (Baker et al., 1988) . The side-chain of PheB25, which adopts an asymmetric con®guration in the crystallographic dimer interface, is not well ordered in either the single-chain or two-chain analogue. Crystallographic protomers do not otherwise yield signi®cant violations when tested against the twochain NMR restraint list.
The solution structure of mini-proinsulin ( Figure 9B ) is indistinguishable from that of the two-chain analogue at the precision obtained (the backbone rms devations (all residues) is 0.88 A Ê relative to the average structure{. In particular, the organization of side-chains in the hydrophobic core is similar in the two structures ( Figure 9C and D). With the exception of imprecision in the B1 to 4 and A1 to A8 segments, the solution structure of the single-chain analogue is similar to that of the T-state crystallographic protomer of mini-proinsulin hexamer (Derewenda et al., 1991 Table 2 re¯ect the former procedure. The latter procedure yields values that are approximately 0.1 A Ê larger for main-chain atoms and 0.3 A Ê larger for side-chain atoms.
{ The main-chain rms deviations between the mean solution structure of the single-chain analogue and that of the two-chain variant is 0.82 A Ê in the well-ordered motiety of the single-chain ensemble (B4 to B24 and A13 to A19; 28 residues) and 0.97 A Ê including the less wellordered A2 to A12 segment (39 residues). Similar values are obtained on comparison of the single-chain variant in solution and a T-state crystallographic protomer of mini-proinsulin (0.98 A Ê and 1.11 A Ê , respectively). These values are also similar to the precision of the singlechain ensemble itself (mean and pairwise main-chain rmsd 0.67 A Ê and 0.96 A Ê for the same 39 residues), indicating that no signi®cant differences in structure can be de®ned at this resolution except as noted as a qualitative perturbation in the A2 to A8 segment (see text).
} The ensemble of single-chain structures also satis®es the two-chain restraint list with the exception of (a) helix-related restraints in the A2 to A8 segment as expected (see Figure 5 ), (b) the presence (single-chain) or absence (two-chain) of a weak long-range NOE between the amide protons of A21 and B22, and (c) a small difference in the orientation of the¯exible N-terminal arm of the B-chain due to the presence (single-chain) or absence (two-chain) of a long-range NOE between Phe B1 H z and Leu A16 d-CH 3 . The latter contact is observed in some crystal structures and not in others.
Structure and Function of Mini-proinsulin however, these NOEs are consistent with one or more T-state crystallographic protomer of native insulin. These observations strongly suggest that the crystal structure of mini-proinsulin is in¯u-enced in its details by hexamer assembly and lattice packing. The observed NOEs are broadly consistent with the repertoire of different crystal forms (Bentley et al., 1978; Chothia et al., 1983; Derewenda et al., 1989; Badger, 1992; Smith & Dodson, 1992; Smith & Ciszak, 1994; Whittingham et al., 1994) even if inconsistent with one particular structure (such as that of mini-proinsulin itself; Derewenda et al., 1991) . We imagine that if miniproinsulin were subjected to as wide a range of crystallographic conditions as has native insulin, that its structure, despite imposition of a B29-A1 peptide bond, would exhibit an analogous repertoire of conformations.
Whereas the solution structure of the singlechain analogue is broadly consistent with the repertoire of crystal structures, this common tertiary framework differs from that of mini-IGF-1. In particular, the core structure of the single-chain (and two-chain) analogue differ from that obtained in NMR studies of mini-IGF-I ( Figure 2C ) despite shared elements of secondary structure. The rms difference between the average positions of mainchain atoms in the mini-proinsulin ensemble relative to those in mini-IGF-I is 4.54 A Ê ; in this alignment the rms difference between identical side chains in the hydrophobic core (residues A2, A16, A19, B11, B12, B15 and B24 and their homologues in mini-IGF-I) is 3.34 A Ê . The rms difference among all side-chains in the two mean structures is 4.94 A Ê {. Because mini-IGF-I was studied in 10% (v/v) deuteroacetic acid and not (as here) in aqueous solution at neutral pH, the present NMR studies were repeated in 20% deuteroacetic acid, conditions previously characterized in studies of native insulin (Weiss et al., 1989; . The results were similar to those obtained in aqueous solution at neutral pH (Supplementary Material). These quantitative differences between mini-proinsulin and mini-IGF-I re¯ect a qualitative spatial rearrangement of shared elements of secondary structure.
Discussion
How does insulin bind to its receptor? That the hormone must undergo a change in conformation was suggested by the ®nding that the crystal structure (Derewenda, U., et al., 1991) of a completely inactive analogue (``mini-proinsulin''; Markussen, 1985a,b) is similar to that of native insulin (Baker et al., 1988) . The analogue's inter-chain peptide bond (asterisk in Figure 1B ) was proposed to constrain the protein from assuming a novel conformation on receptor binding. Implicit in this proposal was the assumption that the crystal structure of mini-proinsulin (as a T 3 R 3 Zn 2 -stabilized hexamer) provides an appropriate model of a monomer in solution. This assumption was challenged by the demonstration that a monomeric`m ini-IGF-I'' exhibits a large-scale reorganization of its tertiary structure and receptor-binding surface (DeWolf et al., 1996; Figures 1C,2C) . Indeed, the rms difference between all main-chain atoms in the mean NMR structure of mini-IGF-I and the mean crystallographic T-state is 4.33 A Ê (50 residues). Does analogous reorganization occur in mini-proinsulin, confounding interpretation of its biological inactivity? To address this question, we prepared by total synthesis a monomeric analogue of mini-proinsulin (B10 Asp , B28 Asp -des B30-single-chain human insu- Structure and Function of Mini-proinsulin lin); the corresponding two-chain analogue was prepared as a control. The results demonstrate that the solution structure of a mini-proinsulin monomer, unlike that of mini-IGF-I, is similar to that of a T-state crystallographic protomer (Baker et al., 1988) . Differences are observed only in the structure or stability of the a-helix adjoining the crosslink (residues A2 to A8). Design of the present analogues re¯ects a hierarchic approach (Bryson et al., 1995) toward the engineering of speci®c dimer, hexamer, and receptor-binding surfaces in an insulin monomer (Brange et al., 1988; Weiss et al., 1991; Brems et al., 1992; Shoelson et al., 1992) . In the course of these studies we found that an engineered mini-proinsulin monomer is not completely inactive, as described in studies of native mini-proinsulin (Derewenda et al., 1991) . Low but signi®cant binding is retained to the insulin receptor; proportionate biological activity is also retained in stimulating lipogenesis in adipocytes (Figure 3) . There are three possible reasons why such residual activity was readily observed in the present study. First, the analogue contains the substitution His B10 3 Asp, which has been shown to enhance the binding and activity of insulin analogues (Schwartz et al., 1987 (Schwartz et al., , 1989 Shoelson et al., 1992) . Second, at high protein concentrations (>1 mM) native insulin begins to form dimers and higher-order oligomers (Goldman & Carpenter, 1974) . Since these species are inactive in receptor binding (Steiner et al., 1990) , self-association can, in principle, confound measurement of biological activity among weakly binding analogues (i.e., those like native mini-proinsulin for which high hormone concentrations would be required to occupy the receptor). Finally, the original assay used in the characterization of mini-proinsulin was insensitive to analogues whose activities were less than 0.1% of that of native insulin (Markussen, 1985b) . In any event the present reinvestigation demonstrates a 1500-fold enhancement in receptor binding on cleavage of the B29-A1 peptide bond.
The large reduction in biological activity of miniproinsulin relative to the two-chain variant cannot be due to simple blocking or unblocking of the chain termini (the A1 a-amino group and B29 carboxylate; Blundell et al., 1972 ). This conclusion is based on three sets of analogue studies. (i) High activity is retained following deletion (Cosmatos et al., 1979) or addition (Markussen et al., 1987) of residues at the C terminus of the B-chain. (ii) Whereas mutation (Cosmatos et al., 1978; Wan & Liang, 1990) or deletion (Brandenburg et al., 1975) of Gly A1 can cause large reductions in activity, high activity is retained after diverse modi®cation of the A1 amino group (such as acetylation or methylation; Brandenburg et al., 1972; Drewes et al., 1981) . (iii) Chemical cross-links between the e-NH 3 group of Lys B29 and the a-NH 3 group of Gly A1 lead to marked reductions in activity for short tethers but high activity for long tethers (Nakagawa & Tager, 1992) . Since the chemical modi®cations at B29 and A1 are the same in each case, relative activities among this set of tethered analogues presumably re¯ect the extent of constraint on conformational adjustments in the hormone.
The large reduction in biological activity of miniproinsulin may, in principle, be due in part to local changes in the structure or stability of the A2 to A8 a-helix. Results of mutagenesis (Kitagawa et al., 1984; Nakagawa & Tager, 1992) , clinical investigation of mutant insulins associated with diabetes mellitus (insulin Wakayama; ) and structural analysis (Baker et al., 1988; Hua et al., 1996b) have together suggested that this helix interacts directly with the insulin receptor. That the observed perturbations are insuf®cient to account for the marked decrement in activity is suggested, however, by the occurence of similar perturbations in the A2 to A8 segment of a variant single-chain analogue with an extended tether (three residues inserted between B29 and A1) and high activity (15% relative to native insulin: Y. M. Feng, Q.X.H. & M.A.W., unpublished results). These and the present results thus support the proposal of Dodson and colleagues that such adjustments are required to optimize af®nity for the insulin receptor (Derewenda et al., 1991) . That the single-chain analogue nevertheless appears to function as a complete agonist (once the receptor is occupied) further suggests that such adjustments are not coupled to the mechanism of transmembrane signaling. This observation does not exclude coupling between receptor triggering and motions elsewhere in the hormone.
The distinct tertiary structures of mini-proinsulin and mini-IGF-I may be regarded as alternative three-dimensional templates for the threading of insulin-like protein sequences. The ®t between these templates and the sequences of the miniproinsulin monomer and mini-IGF-I can be assessed by use of Eisenberg 3D-1D pro®le scores (Bowie et al., 1990; Luthy et al., 1991) . The miniproinsulin template is de®ned by the mean of present DG/SA ensemble; the mini-IGF-I template is de®ned by its mean solution structure. Results (given in Table 3 ) indicate that the two protein sequences yield similar scores when threaded though either template. The sequence of mini-IGF-I discriminates between templates somewhat less well than does the sequence of mini-proinsulin. The overall consistency of each sequence with either template contrasts with the marked structural changes between templates (mean main-chain and side-chain rms differences of 4.54 A Ê and 4.94 A Ê , respectively). These two proteins thus provide examples of homologous sequences encoding non-homologous structures. The corresponding A domains (21 residues) contain 11 sequence identities (asterisks below) and four seemingly conservative substitutions involving solvent-exposed sidechains.
human insulin GIVEQCCTSICSLYQLENYCN human IGF-1 GIVDECCFRSCDLRRLEMYCA *** ** * * ** ** Corresponding B domains (28 residues) contain 14 sequence identities (asterisks) and nine seemingly conservative substitutions involving solvent-exposed side-chains.
human insulin FVNQHLCGSHLVEALYLVCGERGFFYTPKT human IGF-1 -GPETLCGAELVDALQFVCGDRGFYFNKPT *** ** ** *** *** *
In each domain internal non-polar or aromatic side-chains are conserved whereas the surfaces of the protein are divergent. Variant interactions on these surfaces and with solvent must underlie choice of tertiary structures. Global transitions in architecture between homologous sequences, described as``protein alchemy'', has recently been demonstrated in the conversion of a b-sheet motif into an a-helical motif by successive mutagenesis (Dalal et al., 1997) . The present example preserves elements of secondary structure but is remarkable for their reorientation. The two structural templates represent alternative solutions to the three-dimensional problem of how to pack these elements to de®ne a polar surface and non-polar interior.
Proinsulin and pro-IGF-I exhibit a striking difference in their respective foldabilities. Whereas oxidative folding of proinsulin yields a single disul®de pairing scheme (the native state), that of pro-IGF-I yields native and non-native isomers (Hober et al., 1994) . This bifurcating pathway is under thermodynamic control . Mature IGF-I (Hober et al., 1992) and two-chain analogues containing the isolated A and B domains exhibit analogous behavior , demonstrating that the relative stabilities of the native and non-native isomers are controlled by variability among side chains in the A or B domains. The corresponding isomer of proinsulin or insulin can be obtained as a kinetic trap and not as a competing ground state (Hua et al., 1995) . Differences in the sequence of the IGF-I A or B domains (relative to those of proinsulin) that are responsible for its misfolding have not been determined. In the future the responsible mechanism may be brought into focus by comparative studies of proinsulin and pro-IGF-I protein-folding intermediates Hua et al., 1996a) . Because disul®de pairing and mispairing is under thermodynamic (rather than kinetic) control , however, the differences in the outcome of oxidative refolding of proinsulin and IGF-I must re¯ect differences in the relative stabilities of homologous disul®de isomers. These differences are presently not well understood. Likewise, the differences in the sequences of mini-proinsulin and Pro®le scores were calculated by the method of Bowie et al. (1990) .
a An ensemble of mini-proinsulin templates was obtained from the present DG/SA ensemble of the single-chain analogue.
b A single mini-IGF-I template was obtained from the average coordinates reported DG/SA structure (DeWolf et al., 1996) .
c The sequence thread contains Asp B10 and Asp B28 substitutions as in the present monomeric analogue.
mini-IGF-I responsible for their structural differences are not understood ( Figure 1C ). We speculate that these problems are related: that differences in the structures or thermodynamic stabilities of respective proinsulin or IGF-I disul®de isomers will be found to re¯ect, in part, the overall change in tertiary structure between their respective``minimized'' proteins.
In summary, we have described the structure and function of an engineered mini-proinsulin monomer. Comparison with the corresponding two-chain analogue has demonstrated a 1500-fold effect of an inter-chain cross-link on biological activity. This supports the hypothesis that a change in the conformation of insulin is required for highaf®nity binding to the insulin receptor (Derewenda et al., 1991; . Retention of agonist activity further demonstrates that motions restricted by the B29 to A1 peptide cross-link are uncorrelated with the mechanism of signal transduction itself. Structural insight into conformational changes associated with binding are of interest in relation to optimizing insulin therapy (Galloway & Chance, 1994 ) and as a model of protein folding (Chothia et al., 1983) . In particular, comparison of the three-dimensional structures of mini-proinsulin and mini-IGF-I reveals a remarkable change in tertiary structure involving common elements of secondary structure. Future investigation of the origins of this change will provide insight into the transfer of information from sequence to structure. Of particular interest will be the structures of chimeric proteins containing sequences of both parents. The minimal set of substitutions required to convert one tertiary structure to another will provide a novel example of protein alchemy.
Methods Materials
Biosynthetic human insulin (Frank & Chance, 1993) was kindly provided by Eli Lilly & Co. (Indianapolis, IN) . N a -butoxy-carbonylasparaginyl(trityl)-PAM resin (0.52 mmol of amine/g; Calbiochem-Novabiochem Corp.) was used as solid support for synthesis of the single-chain analogue. N a -butoxycarbonyl-N e -2-chlorobenzyloxycarbonyl)lysyl-PAM resin (0.39 mmol/g; Bachem, Inc.) was used as solid support for synthesis of the B-chain analogue. tert-Butoxycarbonyl-amino acids and derivatives were obtained from Bachem and Peninsula Laboratories; N,N H -dicyclohexylcarbodiimide and N-hydroxybenzotriazole (recrystallized from 95% ethanol) from Fluka. Amino acid analyses of synthetic chains and insulin analogue were performed after acid hydrolysis under standard conditions using a Beckman System 6300 high-performance analyzer. Protein determinations were carried out by the Lowry method using native insulin as standard. Chromatography resins were preswollen microgranular carboxymethylcellulose (CM-cellulose; Whatman CM52), DE53 cellulose (Whatman) and Cellex E (Ecteola cellulose; Sigma). Solvents were HPLC grade.
Peptide synthesis
The general protocol for solid-phase synthesis is as described (Barany & Meri®eld, 1979) . A manual doubledecoupling protocol (Merri®eld et al., 1982) was followed as described (Hu et al., 1993) . With the exception of the amino acid following Gln, which was incorporated from preformed symmetric anhydrides (Hagenmaier & Frank, 1972) , the protected amino acids were incorporated from preformed hydroxybenzotriazole esters. From 3.8 g of N a -butoxycarbonyl -N e -2-chlorobenzyloxycarbonyl)lysyl-PAM resin, 8.9 g of peptidyl resin was obtained; using 2.0 g of N a -butoxycarbonylasparaginyl(trityl)-PAM resin as solid support, 9.6 g of peptidyl resin was obtained. Deblocking of the protected polypeptidyl resins on exposure to liquid hydrogen¯uoride and sul®tolysis of the resulting reduced products was performed as described .
Peptide purification
The crude S-sulfonated B-chain was puri®ed by chromatography on a cellulose DE53 column (1.5 cm Â 47 cm) equilibrated with 0.1 M Tris-HCl (pH 7.5). Elution was carried out with a linear NaCl gradient formed by adding to the above buffer (300 ml) 1 M NaCl in the same buffer (300 ml). The ef¯uent corresponding to the major peak (ca. 285 to 385 ml of eluate) was collected, dialyzed as described above and lyophilized.
Synthesis of the two-chain analogue
The S-sulfonated human A-chain was prepared by oxidative sul®tolysis of human insulin for 3.5 hours as described (Katsoyannis et al., 1967a) . The S-sulfonated B-chain analogue (des (Thr B30 )(Asp B10 , Asp B28 )) was prepared by solid-phase synthesis of the protected 29-residue peptide followed by deblocking and sul®tolysis. Chain combination was accomplished in 9 ml of 0.1 M glycine buffer (pH 10.6) in the presence of dithiothreitol (Chance et al., 1981; Hu et al., 1993) . S-Sulfonated A-chain (41.35 mg) and S-sulfonated B-chain analogue (20.15 mg) yielded 5.25 mg of the two-chain insulin analogue after puri®cation with CM-cellulose chromatography (Katsoyannis et al., 1967b) and reverse-phase HPLC (Vydac 218 TP column) as described (Hua et al., 1996b) . Rechromatography of this product by analytical HPLC gave a single peak; its composition (excepting cysteine) was veri®ed by amino acid analysis, and its predicted molecular mass was veri®ed by electrospray mass spectrometry.
Synthesis of mini-proinsulin analogue
The S-sulfonated single-chain polypeptide was prepared by solid-phase synthesis of the protected 50-residue polypeptide followed by deblocking and sul®tolysis. The crude S-sulfonated 50mer was puri®ed by ionexchange HPLC chromatography using a Synchropak AX300 column (10 mm Â 250 mm) as described (Schwartz et al., 1989) . Conversion of the S-sulfonated derivative to a mini-proinsulin analogue was accomplished by: (i) reduction to the sulfhydryl form by 25% (v/v) b-mercaptoethanol in 6 M guanidine-HCl and 10 mM Tris-HCl (pH 8.4); (ii) precipitation of the reduced protein in 1 N HCl by acetone (40:1, v/v) on ice; and (iii) oxidative refolding in 0.09 M Tris-acetate (pH 8.2) in the presence of oxidized and reduced glutathione as described in studies of bovine pancreatic trypsin inhibitor (Ahmed et al., 1975) . The analogue was puri®ed by reverse-phase HPLC on a Waters mBondapak C18 column (3.9 mm Â 300 mm). Aliquots of 0.3 mg were chromatographed at a¯ow rate of 0.5 ml/min with a 30% to 100% linear gradient between buffers A and B over 50 minutes. Buffer A consists of 0.0005 N HCl; buffer B consists of 0.0005 N HCl in 90% (v/v) methanol. Rechromatography of this product by analytical HPLC gave a single peak; its composition (excepting cysteine) was veri®ed by amino acid analysis; and its predicted molecular mass (5684 Da) was veri®ed by electrospray mass spectrometry. Fidelity of disul®de pairing was veri®ed by NMR.
Biological assays
For binding studies using rat insulin receptors, plasma membranes were puri®ed from rat liver. [ H]glucose were purchased from Dupont NEN. These assays were performed as described (Hu et al., 1993; Hua et al., 1996b) .
Spectroscopy
NMR spectra were obtained at 600 MHz at 25 C in 50 mM potassium phosphate (pH 7) as described (Hua et al., 1996b) ; the protein concentration was 1.5 mM. Resonance assignment was based on 2D NOESY (mixing times 100 and 200 ms), TOCSY (mixing times 30 and 55 ms), and DQF-COSY spectra (Kline & Justice, 1990) . Spectra in H 2 O were obtained using pulse-®eld gradients and laminar shaped pulses.
Structural modeling
Ensembles were calculated by DG/SA (Havel, 1991) as described (Hua et al., 1995 (Hua et al., , 1996b . In brief, initial models were obtained by DG/SA using the program DG-II (Havel, 1991) as implemented in Insight-95 (Biosym, Inc., San Diego, CA) and re®ned using X-PLOR (Bru È nger, 1992) . Distance restraints were obtained from the intensities of NOESY cross-peaks classi®ed as strong (<2.7 A Ê ), medium (<3.4 A Ê ) or weak (5.0 A Ê ). Pseudo-atom corrections for methylene, methyl and the ortho (and meta) resonances of Phe and Tyr were 1.0 A Ê , 1.0 A Ê , and 2.0 A Ê , respectively. Dihedral f restraints were obtained from 3 J HNa coupling constants (À65 (AE 25) for J < 6 Hz and À120 (AE40) for J > 8 Hz). Coupling constants were obtained at pH 7 and in 20% deuteroacetic acid from DQF-COSY spectra as described (Kim & Prestegard, 1990) . Because of the larger variability of amide line widths in the spectrum of the single-chain analogue, measurement of small couplings was limited in part by antiphase cancellation. In the B9± B19 and A12 ± A18 a-helices (well de®ned by NOEs) analogous dihedral restraints were imposed as obtained for the two-chain variant. Hydrogen bond restraints (two distances per hydrogen bond) were imposed at sites of protected amide proton exchange; use of a-helix-speci®c hydrogen bonds was supported by observation of weak d aN(i,i 4) and d bN(i,i 4) NOEs in accord with a previous study (see the legand to Figure 5 ; Ludvigsen et al., 1994) . Solvent accessibilities were calculated using X-PLOR. Molecular graphics was obtained using the InsightII package (Hua et al., 1993a,b) .
